SBIR & Research
SBIR Phase 1 vs Phase 2: Key Differences Explained
Grant Writing Service Editorial Team
June 12, 2026 · 5 min read
Table of contents
Key takeaways
- Phase I tests whether the core idea is technically feasible; Phase II funds the research and development to turn a validated concept into a near-market product.
- At NSF today, Phase I is up to $305,000 over 6 to 18 months and Phase II up to $1,250,000 over about 24 months; other agencies set their own amounts.
- Phase II normally requires a Phase I award, but Fast-Track and, at some agencies, Direct to Phase II offer other routes.
- Phase III is commercialization paid for with non-SBIR money, though it carries special contracting advantages.
SBIR Phase I is a smaller, shorter award that tests whether an idea is technically feasible; Phase II is a larger, longer award that funds the full research and development of a concept Phase I validated. Phase I asks "can it work?" and Phase II asks "can we build it into something people will buy?" You normally need a Phase I award before applying for Phase II, although Fast-Track applications and, at some agencies, Direct to Phase II offer other routes.
Side by side
| Phase I | Phase II | |
|---|---|---|
| Purpose | Prove technical merit and feasibility | Full research and development toward a product |
| Award size | NSF: up to $305,000. Other agencies set their own, within SBA guidelines | NSF: up to $1,250,000. Other agencies set their own, often larger at NIH |
| Duration | NSF: 6 to 18 months. NIH: normally 6 months for SBIR and 1 year for STTR, with longer periods allowed when justified | Typically about 24 months |
| Review emphasis | Feasibility first; commercial potential supports it | Technical progress plus a detailed commercialization case |
| Who can apply | Any eligible small business | Normally Phase I awardees of the same agency |
| NIH activity code | R43 (SBIR), R41 (STTR) | R44 (SBIR), R42 (STTR) |
Award ceilings come from SBA guidelines that are adjusted for inflation, and agencies can go above them for specific topics with an SBA waiver. The figures above are from NSF's current solicitation (NSF 26-510); for any other agency, take the number from its current solicitation rather than an article, because amounts change between cycles.
Phase I: proving feasibility
Phase I exists to answer one question: is the core technical idea sound enough to justify a larger investment? A good Phase I scope is narrow: one central feasibility question, usually two aims or objectives, and numeric success criteria that tell the reviewer what result would count as proof. It is not the place to build a finished product.
Commercialization is scored at Phase I but in a supporting role. Reviewers want a credible customer, market, and business model, often in a page or a few pages. Our guide to writing an SBIR proposal for each agency's format covers what each section needs, and our worked SBIR Phase I aims page shows a feasibility scope with success criteria.
Phase II: building the product
Phase II funds the heavy development that moves a proven concept toward market: prototypes, scale-up, validation studies, and early regulatory work. The application must show what Phase I achieved against its stated criteria, then lay out a larger technical plan.
The commercial case moves from supporting to central. At NIH, Phase II requires a Commercialization Plan of up to 12 pages covering the company, market, intellectual property, regulatory path, financing, and revenue. Our guide to the SBIR commercialization plan at each agency covers what reviewers look for.
Timing matters too. At NSF, Phase I awardees can submit a Phase II proposal between 6 and 24 months after their Phase I start date. Other agencies have their own windows, so check yours before Phase I ends.
Other routes between the phases
- Fast-Track combines Phase I and Phase II in one application, reviewed together, so a company that meets its Phase I milestones moves into Phase II without a second competition. NSF's current Fast-Track offers about $1.56 million in combined funding and requires an invited Project Pitch; NIH also accepts Fast-Track applications.
- Direct to Phase II lets a company that has already shown feasibility with other funding skip Phase I. NIH has offered it through its omnibus small-business announcement; check the current announcement to confirm it is accepted and what evidence of feasibility is required.
- Phase IIB provides more money after Phase II. Some NIH institutes offer competing renewals for products that need lengthy regulatory work; NSF offers Phase IIB supplements of $50,000 to $500,000 to Phase II awardees.
- Strategic Breakthrough awards, created by the April 2026 reauthorization, allow much larger Phase II awards at agencies with large SBIR budgets. NSF's version allows up to $30,000,000, by invitation, for Phase II awardees.
The gap between Phase I and Phase II
Phase I money ends before a Phase II decision arrives. The Phase II application must be written, submitted, reviewed, and awarded, which can take many months, and a small company with no other revenue risks losing the team that made Phase I work.
Three moves reduce the damage. Start drafting Phase II while Phase I is still running, so you can submit at the first eligible deadline with fresh data. Consider Fast-Track from the outset if your milestones are well defined. And line up interim funding, whether internal funds, an investor bridge, or non-SBIR revenue, before Phase I closes. The 2025 to 2026 lapse, when agencies could make no new awards for about six months, was a reminder that federal timelines can stall for reasons that have nothing to do with your project.
Phase III: commercialization
Phase III is where the technology reaches the market or a government customer, and it is funded with money other than SBIR awards: private investment, sales, or non-SBIR government contracts. It still carries real advantages. Federal agencies can award Phase III contracts that derive from SBIR work without a new competition, and SBIR data rights protect your technical data from disclosure for a period after the award. For defense technologies in particular, planning for Phase III early can shape which topics you pursue in Phase I.
Odds at each phase
Phase II pools are smaller and made up of companies that already won Phase I, so Phase II success rates usually look higher. That reflects a stronger field, not an easier bar. For what the published data actually show, see our breakdown of the SBIR success rate by agency. If you want a team to plan and write the sequence for you, our SBIR and STTR grant writing service covers Phase I, Phase II, and Fast-Track applications.
